Completed PHASE2 INTERVENTIONAL NCT00003881

Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC

Sponsor: Eastern Cooperative Oncology Group

Interventions carboplatin paclitaxel trastuzumab

Updated 6 times since 2017 Last updated: Jun 20, 2013 Started: May 31, 1999 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003881, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Brooklyn, United States , Cedar Rapids, United States , Chicago, United States , Cleveland, United States , Columbus, United States and 44 more locations